📻𝗜𝗔𝗖𝗛 𝗥𝗮𝗱𝗶𝗼: 𝗢𝗻 𝗔𝗶𝗿 𝗳𝗿𝗼𝗺 #EHA2025 𝘗𝘰𝘰𝘭𝘦𝘥 𝘍𝘦𝘤𝘢𝘭 𝘈𝘭𝘭𝘰𝘨𝘦𝘯𝘪𝘤 𝘔𝘪𝘤𝘳𝘰𝘣𝘪𝘰𝘵𝘩𝘦𝘳𝘢𝘱𝘺 𝘧𝘰𝘳 𝘙𝘦𝘧𝘳𝘢𝘤𝘵𝘰𝘳𝘺 𝘎𝘢𝘴𝘵𝘳𝘰𝘪𝘯𝘵𝘦𝘴𝘵𝘪𝘯𝘢𝘭 𝘈𝘤𝘶𝘵𝘦 𝘎𝘳𝘢𝘧𝘵-𝘷𝘦𝘳𝘴𝘶𝘴-𝘏𝘰𝘴𝘵 𝘋𝘪𝘴𝘦𝘢𝘴𝘦 iach.org/iach-news-podcasts/ @EHA_Hematology @Mohty_EBMT

Live at #EHA2025 - proud to see Prof. Mohty @Mohty_EBMT presenting promising data for GvHD patients treated with Xervyteg!

📄 [Press release] – MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT 🩸 Key highlights: ✅ The independent DSMB has recommended that the study proceed without modification. ✅ Favorable safety profile and tolerability for MaaT033, a standardized pooled donor-derived drug candidate in oral formulation. Upcoming milestones: ▪ Next DSMB unblinded interim analysis with mortality monitoring scheduled for Q3 2025 at the 120-patient mark. ▪ Routine DSMB review for ongoing safety also expected for Q3 2025. 👉Read the press release here: maatpharma.com/april-8-2025-… #Hematology #Oncology #BloodCancer #Cancer #DSMB #Safety #Tolerability #Phase2 #Microbiome #Microbiota

📄[Communiqué de presse] – MaaT Pharma annonce le résultat positif de l’analyse intermédiaire de sécurité du DSMB pour l'essai clinique de Phase 2b en cours évaluant MaaT033 pour les patients recevant une allo-GCSH 🩸 Points clés : ✅ Le DSMB a recommandé la poursuite de l'essai sans modification. ✅ Profil de sécurité favorable et une bonne tolérance pour MaaT033, un candidat-médicament standardisé de forme orale développé à partir de plusieurs donneurs. Prochaines étapes : · Prochaine analyse intermédiaire après la levée d’aveugle par le DSMB prévue au troisième trimestre 2025, après l’inclusion du 120ème patient. · Evaluation de sécurité régulière du DSMB aussi attendue pour le troisième trimestre 2025. 👉Lire le communiqué de presse ici : maatpharma.com/fr/8-avril-20… #Oncologie #CancersDuSang #Cancer #DSMB #Sécurité #Tolérabilité #Phase2 #Hématologie #Microbiome #Microbiote

📰 MaaT Pharma in @LePoint! We’re proud to be featured in the special issue “Ces projets qui façonnent la santé du futur” (Shaping the future of healthcare), written by Valérie Peiffer and Raphaël Ruffier-Fossoul, highlighting our pioneering work in restoring gut microbiome functions to support patients with life-threatening conditions, especially in oncology. Newspaper available at newsstands or via this link: lepoint.fr/versions-numeriqu…

📰 More Great Media Coverage for our positive safety update for MaaT033 in Phase 2b trial! We’re proud to see @InvestirFr Les Echos cover the DSMB’s favorable interim safety assessment in our ongoing study in allo-HSCT patients. 👉 Read the article here: investir.lesechos.fr/actu-de… 📰 Nouvelle belle couverture médiatique pour notre actualité sur MaaT033 ! Nous sommes fiers de voir @InvestirFr Les Echos relayer l’analyse intermédiaire de sécurité favorable menée par le DSMB dans le cadre de notre essai clinique de Phase 2b chez les patients recevant une allo-GCSH. 👉Lire l’article ici : investir.lesechos.fr/actu-de… #Microbiome #AlloHSCT #ClinicalTrials #MaaT033 #DSMB #Safety #Phase2

📰 #Media - We’re proud to be featured for the first time in Het Financieele Dagblad @FD_Nieuws, a leading Dutch financial daily newspaper, In an article highlighting the thriving life sciences ecosystem in Lyon, the piece includes our recent clinical milestones, our manufacturing capacities and our regulatory ambitions — all driven by our pioneering work in microbiome science. We're proud to be included alongside other key institutions and innovative companies helping to shape the future of life sciences: @sanofi @biomerieux @Boehringer @Lyonbiopole @OsivaxVaccines @WHO_Europe 👉 Read the article here: fd.nl/bedrijfsleven/1550491/… Thank you @OnlyLyon and Florent Gerbaud for the great opportunity. #Oncology #Biotech #ClinicalTrials #Innovation #Lyon

📄 [Communiqué de Presse] – MaaT Pharma annonce la mise à disposition du Document d’Enregistrement Universel (DEU) 2024 👉 Accéder au document : maatpharma.com/fr/investisse…

📄 [Press release] – MaaT Pharma Announces the Availability of its 2024 Universal Registration Document (URD) 👉 Access the document: maatpharma.com/investors/#in…

📢 [#EVENT] - We are proud to share that Bastien Laperrousaz, our Director of Preclinical Development, will be presenting at the American Association for Cancer Research @AACR Annual Meeting 2025. He will comment on promising preclinical data for MaaT034, our synthetic microbiome therapy, designed to improve patients’ responses to immunotherapies. 📅 April 25-30, 2025 📍 Chicago, Illinois Stay tuned for more on how microbiome modulation could support the future of cancer care. #AACR2025 #Immunotherapies #Microbiome #Cancer #Oncology #Innovation #Research #Preclinical

💡 [#WorldCancerDay 2025] - There’s never been a more exciting time in #microbiome #research, especially in #oncology. We’re proud that our ARES trial is contributing to the field, and to a potential breakthrough treatment. Learn more from Professor @Mohty_EBMT on what it could mean for #patients. #Oncology #Hematology #aGvHD #Cancer

📰 - MaaT Pharma in Bloomberg @business - We’re proud to see our work featured in Bloomberg, spotlighting the potential of microbiome therapy in cancer care. The article and film share the inspiring patient’s story, who overcame aGvHD, a life-threatening complication after a stem-cell transplant, and includes a testimonial from Dr. Loschi, who treated her through the Early Access Program. Thank you to Jason Gale @jwgale for writting avout the potential of microbiome-based therapies beyond infectious diseases. 🔗 Read the full Bloomberg article: bloomberg.com/news/articles/… 🔗 Watch the video on Bloomberg Originals: youtube.com/watch?v=P8pd0TlI… #Bloomberg #MicrobiomeTherapy #CancerCareInnovation #GVHD #Microbiome #Hematology #Oncology #JPM2025

.@MaaT_Pharma 's MaaT013 has the potential to be the first approved third-line treatment option & transform the survival outcomes and redefine long-term prospects for approximately 3,000 third-line GI-aGvHD patients per year in the U.S., Canada & Europe. bit.ly/3Wd57jk

📄[Press release] – MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT🩸 maatpharma.com/january-21-20… #Microbiome #BloodCancer #Cancer #DSMB #Safety #Tolerability #Phase2

📄[Communiqué de presse] – MaaT Pharma annonce le résultat positif du deuxième DSMB pour l'essai clinique de Phase 2b en cours évaluant MaaT033 pour les patients recevant une allo-GCSH 🩸 👉maatpharma.com/fr/21-janvier… #Microbiote #CancersDuSang #Cancer #DSMB #Sécurité #Tolérabilité #Phase2

Steep streets of #SanFrancisco are like the entrepreneur's journey: full of uphill climbs, unexpected turns, and rewarding views at the top. No exception during #JPM2025, every climb leads to a breathtaking view. 🚋✨ #Entrepreneurship #GoodVibes @MaaT_Pharma

🎥 Behind the scenes in San Francisco! MaaT Pharma’s CEO, @Herve Affagard @HAffagard sat down today with @FierceBiotech 's Rebecca Willumson @RebeccaEFriend during #JPM2025 for an exclusive interview. They discussed our exciting Phase 3 ARES data announcement and what’s ahead for MaaT Pharma in 2025. Stay tuned—the full video will be shared in the coming weeks. #Cancer #Oncology #MicrobiomeInnovation #Biotech #HealthcareTransformation

For all of those who are taking the #Patients angle when participating to the advent of the #Microbiome field, do check this excellent 12 mins video from @jwgale featuring @MaaT_Pharma youtube.com/watch?v=P8pd0TlI…

ARES Trial of MaaT013 in GI-aGVHD Meets Primary End Point of GI-ORR @Mohty_EBMT @HopSaintAntoine @sorbonne_univ_ #oncology onclive.com/view/ares-trial-…